Pfizer Inc. (NYSE:PFE) Shares Acquired by Core Wealth Partners LLC

Core Wealth Partners LLC boosted its position in Pfizer Inc. (NYSE:PFE) by 6.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,505 shares of the biopharmaceutical company’s stock after buying an additional 1,115 shares during the quarter. Core Wealth Partners LLC’s holdings in Pfizer were worth $491,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. America First Investment Advisors LLC lifted its stake in shares of Pfizer by 0.5% in the fourth quarter. America First Investment Advisors LLC now owns 653,444 shares of the biopharmaceutical company’s stock worth $17,336,000 after acquiring an additional 3,190 shares in the last quarter. Ausdal Financial Partners Inc. increased its holdings in Pfizer by 66.7% during the 4th quarter. Ausdal Financial Partners Inc. now owns 25,658 shares of the biopharmaceutical company’s stock worth $681,000 after purchasing an additional 10,262 shares during the last quarter. Financial Engines Advisors L.L.C. acquired a new position in shares of Pfizer in the 4th quarter valued at approximately $384,000. Summitry LLC purchased a new position in shares of Pfizer during the 4th quarter valued at approximately $228,000. Finally, Murphy & Mullick Capital Management Corp acquired a new stake in shares of Pfizer during the fourth quarter worth approximately $235,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent analyst reports. Truist Financial cut their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Bank of America restated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Finally, UBS Group decreased their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Stock Performance

Shares of PFE opened at $25.56 on Wednesday. The firm has a fifty day moving average of $26.14 and a 200-day moving average of $27.00. The company has a market cap of $144.96 billion, a price-to-earnings ratio of 18.13, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same period in the previous year, the business posted $0.10 EPS. Pfizer’s revenue was up 24.7% on a year-over-year basis. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.